Effectiveness of transarterial chemoembolization in combination with lenvatinib and programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma

doi:10.4251/wjgo.v16.i7.2884

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (185)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

158

Sum=165

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=16

Jul 15, 2024 (publication date) through Jul 15, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastrointest Oncol. Jul 15, 2024; 16(7): 2884-2887
Published online Jul 15, 2024. doi: 10.4251/wjgo.v16.i7.2884

Effectiveness of transarterial chemoembolization in combination with lenvatinib and programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma

Meer M Chisthi

Meer M Chisthi, Department of General Surgery, Government Medical College Pathanamthitta, Konni 689691, Kerala, India

Author contributions: Chisthi MM was responsible for all work on the manuscript.

Conflict-of-interest statement: Dr. Chisthi declares having no conflicts of interest to disclose.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Meer M Chisthi, MBBS, MS, Professor, Surgeon, Department of General Surgery, Government Medical College Pathanamthitta, Aanakuthi, Konni 689691, Kerala, India. meerchisthi@gmail.com

Received: February 27, 2024
Revised: April 18, 2024
Accepted: April 29, 2024
Published online: July 15, 2024
Processing time: 136 Days and 5.8 Hours

Core Tip

Core Tip: Transarterial chemoembolization (TACE) combined with lenvatinib and programmed cell death protein-1 (PD-1) inhibitors presents an encouraging therapeutic approach for unresectable hepatocellular carcinoma (HCC). This triple therapy demonstrates well-tolerated outcomes with a median overall survival of 26.43 months and a median progression-free survival of 10.07 months. Notably, patients with Barcelona Clinic Liver Cancer B-stage, exhibiting early neutrophil-to-lymphocyte ratio and alpha-fetoprotein responses, show superior clinical outcomes. Understanding these predictive factors can guide treatment decisions and enhance the efficacy of TACE/lenvatinib/PD-1 therapy in unresectable HCC.